Studies of targeting and intracellular trafficking of an anti-androgen doxorubicin-formaldehyde conjugate in PC-3 prostate cancer cells bearing androgen receptor-GFP chimera

Journal of Medicinal Chemistry

Volumn 47, Issue 23, 2004, Pages 5690-5699

  Cogan, Peter S ^b   Koch, Tad H ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTHRAQUINONE; ANTIANDROGEN; DOXORUBICIN; DOXORUBICIN DERIVATIVE; FLUTAMIDE; FORMALDEHYDE; GREEN FLUORESCENT PROTEIN; MIBOLERONE; NILUTAMIDE; SALICYLAMIDE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CANCER CELL; CHIMERA; DRUG BINDING; DRUG CONJUGATION; DRUG DESIGN; DRUG INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PROSTATE CANCER; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; TRANSLOCATION LINE; TUMOR LOCALIZATION;

ANDROGEN ANTAGONISTS; DOXORUBICIN; FORMALDEHYDE; GREEN FLUORESCENT PROTEINS; HUMANS; IMIDAZOLES; LIGANDS; MALE; MANNICH BASES; MICROSCOPY, FLUORESCENCE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECOMBINANT FUSION PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 7544250465     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0495226     Document Type: Article

References (36)

1. Fenick, D. J.; Taatjes, D. J.; Koch, T. H. Doxoform and Daunoform: Anthracycline-formaldehyde conjugates toxic to resistant tumor cells. J. Med. Chem. 1997, 40, 2452-2461.
2. Dernell, W. S.; Powers, B. E.; Taatjes, D. J.; Cogan, P.; Gaudiano, G. et al. Evaluation of the epidoxorubicin-formaldehyde conjugate, epidoxoform, in a mouse mammary carcinoma model. Cancer Invest. 2002, 20, 712-723.
3. Cutts, S. M.; Rephaeli, A.; Nudelman, A.; Hmelnitsky, I.; Phillips, D. R. Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9). Cancer Res. 2001, 61, 8194-8202.
4. Swift, L. P.; Cutts, S. M.; Rephaeli, A.; Nudelman, A.; Phillips, D. R. Activation of Adriamycin by the pH-dependent formaldehyde-releasing prodrug hexamethylenetetramine. Mol. Cancer Ther. 2003, 2, 189-198.
5. Cogan, P. S.; Fowler, C. R.; Post, G. C.; Koch, T. H. Doxsaliform: a novel N-Mannich base prodrug of a doxorubicin formaldehyde conjugate. Lett. Drug Des. Dis. 2004, 1, 247-255.
6. Taatjes, D. J.; Fenick, D. J.; Koch, T. H. Epidoxoform: a hydrolytically more stable anthracycline-formaldehyde conjugate, cytotoxic to resistant tumor cells. J. Med. Chem. 1998, 41, 1306-1314.
7. Zeman, S. M.; Phillips, D. R.; Crothers, D. M. Characterization of covalent Adriamycin-DNA adducts. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 11561-11565.
8. Podell, E. R.; Harrington, D. J.; Taatjes, D. J.; Koch, T. H. Crystal structure of epidoxorubicin-formaldehyde virtual cross-link of DNA and evidence for its formation in human breast-cancer cells. Acta Crystallogr. 1999, D55, 1516-1523.
9. Taatjes, D. J.; Fenick, D. J.; Koch, T. H. Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines. Chem. Res. Toxicol. 1999, 12, 588-596.
10. Cullinane, C.; Cutts, S. M.; Panousis, C.; Phillips, D. R. Interstrand cross-linking by Adriamycin in nuclear and mitochondrial DNA of MCF-7 cells. Nucleic Acid. Res. 2000, 28, 1019-1025.
11. Anderson, W. F.; Chatterjee, N.; Ershler, W. B.; Brawley, O. W. Estrogen receptor breast cancer phenotypes in surveillance, epidemiology, and end results databases. Breast Cancer Res. Tr. 2002, 76, 27-36.
12. Burke, P. J.; Koch, T. H. Design, synthesis, and biological evaluation of doxorubicin-formaldehyde conjugates targeted to breast cancer cells. J. Med. Chum. 2004, 47, 1193-1206.
13. Zitzmann, S.; Ehemann, V.; Schwab, M. Arginine-glycineaspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res. 2002, 62, 5139-5143.
14. Arap, W.; Oasqualini, R.; Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998, 279, 377-380.
15. Cogan, P. S.; Koch, T. H. Rational design and synthesis of androgen receptor-targeted nonsteroidal anti-androgen ligands for the tumor specific delivery of a doxorubicin-formaldehyde conjugate. J. Med. Chem. 2003, 46, 5258-5270.
16. Ruizeveld de Winter, J. A.; Trapman, J.; Vermey, M.; Mulder, E.; Zegers, N. et al. Androgen receptor expression in human tissues: an immunohistochemical study. J. Histochem. Cytochem. 1991, 39, 927-936.
17. Brys, M. Androgens and androgen receptor: do they play a role in breast cancer? Med. Sci. Monit. 2000, 6, 433-438.
18. Hall, R.; Clements, J.; Birrell, S.; Tilley, W. Prostate-specific antigen and gross cystic disease fluid protein-15 are coexpressed in androgen receptor-positive breast tumors. Br. J. Cancer. 1998, 78, 360-365.
19. Engehausen, D. G.; Tong, X.; Oehler, M. K.; Freund, C. T.; Schrott, K. M. et al. Androgen receptor gene mutations do not occur in ovarian cancer. Anticancer Res. 2000, 20, 815-819.
20. Tihan, T.; Harmon, J. W.; Wan, X.; Younes, Z.; Nass, P. et al. Evidience of androgen receptor expression in squamous and adenocarcinoma of the esophagus. Anticancer Res. 2001, 21, 3107-3114.
21. Kaiser, U.; Hofmann, J.; Schilli, M.; Wegmann, B.; Klotz, U. et al. Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int. J. Cancer. 1996, 67, 357-364.
22. Adiga, S. K.; Andritsch, I.; Rao, R. V.; Krishan, A. Androgen receptor expression and DNA content of paraffin-Embedded archival human prostate tumors. Cytometry. 2002, 50, 25-30.
23. Shi, X.; Ma, A.; Xia, L.; Kung, H.; de ver White, R. W. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res. 2002, 62, 1496-1502.
24. Georget, V.; Lobaccaro, J. M.; Terouanne, B.; Mangeat, p.; Nicolas, J. et al. Trafficking of the androgen receptor in living cells with fused green fluorescent protein-androgen receptor. Mol. Cell Endocrinol. 1997, 129, 17-26.
25. Veldscholte, J.; A., B. C.; Brinkman, A. O.; Grootegoed, A.; Mulder, E. Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 1992, 31, 2393-2399.
26. Tyagi, R. K.; Lavorvsky, Y.; Ahn, S. C.; Song, C. S.; Chatterjee, B. et al. Dynamics of intercellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells. Mol. Endocrinol. 2000, 14, 1162-1174.
27. Linja, M. J.; Savinainen, K. J.; Saramäki, O. R.; Tammela, T. L. J.; Vessella, R. L. et al. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 2001, 61, 3550-3555.
28. Tomura, A.; Goto, K.; Morinaga, H.; Nomura, M.; Okabe, T. et al. The subnuclear three-dimensional image analysis of androgen receptor fused to green fluorescent protein. J. Biol. Chem. 2001, 276, 28395-28401.
29. Georget, V.; Terouanne, B.; Nicolas, J.; Sultan, C. Trafficking of the androgen receptor. Methods Enzymol. 1999, 302, 121-135.
30. Dai, J. L.; Maiorino, C. A.; Gkonus, P. J.; Burnstein, K. L. Androgenic up-regulation of androgen receptor cDNA expression in androgen-independent prostate cancer cells. Steroids 1996, 61, 531-539.
31. Georget, V.; Terouanne, B.; Nicolas, J.; Sultan, C. Mechanism of antiandrogen action: key role of Hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry. 2002, 41, 11824-11831.
32. Crooke, S. T.; DuVernay, V. H. Fluorescence quenching of anthracyclines by subcellular fractions. Anthracyclines Current Status and New Developments; Academic Press: New York, 1980; pp 151-155.
33. Roche, C. J.; Thomson, J. A.; Crothers, D. M. Site selectivity of daunomycin. Biochemistry 1994, 33, 926-935.
34. Gallois, L.; Fiallo, M.; Laigle, A.; Priebe, W.; Garnier-Sullerot, A. The overall partitioning of anthracyclines into phosphatidyl-containing model membranes depends neither on the drug charge nor the presence of anionic phospholipids. Eur. J. Biochem. 1996, 241, 879-887.
35. Pichon, C.; Monsigny, M.; Roche, A.-C. Intracellular localization of oligonucleotides: influence of fixative protocols. Antisense Nucleic Acid Drug Dev. 1999, 9, 89-93.
36. Bundgaard, H.; Klixbull, U.; Falch, E. Prodrugs as drug delivery systems. 43. O-acyloxymethyl salicylamide N-Mannich bases as double prodrug forms for amines. Int. J. Pharm. 1986, 29, 19-28.